Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

So the pre-prints or the peer reviewed article publications are preliminary. They provide documentation of some research and I agree with your characterizations, but this isn't consistent with history:
"I just can't imagine an article not based on a successful P-3 or even a strong 2b busting the pps up much".

Here's my example:
June 17, 2020
"Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line"

It didn't matter that few understood what that meant exactly (some still don't, present company included). Intraday prices ran from $.16 to $.65 in the next few days. So the right news CAN bust the pps up plenty.
But it's not $.65 any more. And the fact that the pps gave up almost all of that gain SUGGESTS that it wasn't deserved in the first place.

The pre-print and peer reviews aren't like a Company release. The scientific community WILL read them and whereas they might discount...in all likelihood actually ignore...the science reported via Globe Newswire, the pre-print and its formalized version will make the underlying facts understandable to people who are capable of understanding their real meaning, versus small cap message board investors (as the saying goes, all due respect).

I would expect much busting UP of the share price if the pre-print finds some fancy, but unqualified and understandable way of saying that Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line. I think the real determinative issue regarding the share price reaction will be whether the pre-print does that, not the fact that it would still be preliminary to "a successful P-3 or even a strong 2b".